Medical Castration Using the Investigational Oral GnRH Antagonist TAK-385 (Relugolix): Phase 1 Study in Healthy Males.

@article{Maclean2015MedicalCU,
  title={Medical Castration Using the Investigational Oral GnRH Antagonist TAK-385 (Relugolix): Phase 1 Study in Healthy Males.},
  author={David B. Maclean and Hongliang G Shi and H{\'e}l{\`e}ne Faessel and Fred Saad},
  journal={The Journal of clinical endocrinology and metabolism},
  year={2015},
  volume={100 12},
  pages={
          4579-87
        }
}
CONTEXT TAK-385 is a highly selective, oral, nonpeptide GnRH antagonist being investigated as a possible prostate cancer treatment. OBJECTIVE The objectives were to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics of TAK-385 on LH and testosterone. DESIGN, SETTING, AND PARTICIPANTS This was a three-part, randomized, double-blind, placebo-controlled, phase 1 dose-escalation study in 176 healthy male UK volunteers. INTERVENTIONS Part 1, single doses of TAK-385 (0… CONTINUE READING
BETA
3
Twitter Mentions

Similar Papers

References

Publications referenced by this paper.
SHOWING 1-10 OF 22 REFERENCES

Guidelines on Prostate Cancer

VIEW 11 EXCERPTS
HIGHLY INFLUENTIAL